EQ-5D: a plea for accurate nomenclature

by Richard Brooks, Kristina S. Boye, Bernhard Slaap
Published 2020-07-01

Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and plac...

by Shuichi Suzuki, Tomonori Oura, Masakazu Takeuchi, Kristina S. Boye
Published 2017-06-01

Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ)

by Kristina S. Boye, Louis S. Matza, Brooke M. Currie, Karin S. Coyne
Published 2020-12-01

Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes

by Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Evan W. Davies, Rosirene Paczkowski
Published 2017-11-01

Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)

by Louis S. Matza, Katie D. Stewart, Rosirene Paczkowski, Karin S. Coyne, Brooke Currie, Kristina S. Boye
Published 2018-09-01

Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)

by Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Rosirene Paczkowski, Jessica Jordan, Lindsey T. Murray
Published 2018-09-01

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK

by Kristina S. Boye, Dara Stein, Louis S. Matza, Jessica Jordan, Ren Yu, Kirsi Norrbacka, Syed Wasi Hassan, Luis-Emilio García-Pérez
Published 2019-05-01